chr17:37868196:> Detail (hg19) (ERBB2)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr17:37,868,196-37,881,332 |
hg38 | chr17:39,711,943-39,725,079 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
bladder carcinoma | Platinum Compound | C |
![]() |
![]() |
Sensitivity/Response | Somatic | 3 | 25636205 | Detail |
breast cancer | Neratinib | B |
![]() |
![]() |
Sensitivity/Response | Somatic | 4 | 28679771 | Detail |
lung non-small cell carcinoma | Pertuzumab,Trastuzumab | B |
![]() |
![]() |
Sensitivity/Response | Somatic | 2 | 29320312 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemot... | CIViC Evidence | Detail |
16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of t... | CIViC Evidence | Detail |
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- Genome
- hg19
- Position
- chr17:37,868,196-37,881,332
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- MUTATION
- Transcript 1 (CIViC Variant)
- ENST00000269571.5
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/666
Genome browser